Antibiotic resistance fund aims 2-4 new antibiotics by 2030, page-6

larrybird, yes it may be so, but I feel that this what you and Stamler say is related to neurodegeneration, not to antibiotic-resistance treatments lasting only some weeks. But the PBT2 molecule may still be in partial clinical hold. Prana wanted to get a higher dosage, FDA insisted lower dosage causing a "partial" hold. Now the worry is not the dogs but 700.000 who die. But you are right, clinical studies need FDA permission. I think that will be taken care of by the buyer who will also do the pharmacokinetic experiments at different dosages. But we can only guess, nothing is told.